DowpharmaSM and Cygnus Technologies, Inc. Announce Launch of Pseudomonas fluorescens Host Cell Protein Kit

Dowpharma^SM and Cygnus Technologies, Inc. Announce Launch of Pseudomonas fluorescens Host Cell Protein Kit
Kit intended for release testing of biopharmaceuticals expressed in Pseudomonas fluorescens

Midland, MI and Southport, NC - April 30, 2007

Dowpharma^SM, a business unit of The Dow Chemical Company, and Cygnus Technologies, Inc. today announced that Cygnus has launched a new kit for testing for the presence of host cell proteins in proteins expressed in Pseudomonas fluorescens.

“This new kit will enable users of Dowpharma Pfēnex Expression Technology™ to routinely test their products for the presence of host cell protein with a fully validated method,” said Charles Squires, R&D director, Dowpharma. “Cygnus Technology is the leading provider of cell protein detection kits and we are very happy that they decided to develop and launch a kit for Pseudomonas fluorescens.”

Ken Hoffman, president at Cygnus Technologies said, “More and more pharmaceutical and biotech companies have been adopting the Pfēnex Expression Technology, and we have responded to this growing need by providing a fully validated test that will satisfy the industry’s need for accurate, rapid and cost-effective QC measures.”

About Cygnus Technologies, Inc.

Cygnus Technologies, Inc. provides the Biotechnology and Biopharmaceutical industry with products and analytical methods, designed to accelerate the R&D phase, improve process development and reduce the costs associated with labor intensive quality control procedures. We offer a comprehensive menu of well validated convenient to use microtiter plate ELISA methods to detect Host Cell Proteins from specific recombinant expression systems and bioprocess contaminants used in culture media as well as transgenic expression systems in goats and cattle. These simple-to-use kits are highly sensitive and are intended to aid in optimal purifications process development and routine quality control.

More information about Cygnus can be found at www.cygnustechnologies.com

About Pfēnex Expression Technology™

Using a natural isolate of Pseudomonas fluorescens, an abundant and non-infectious component of the microbial flora of soil, water, and plants, many high performance production strains have been developed. Proteins are expressed in high yields with correct disulfide bond formation, reduced proteolytic degradation and enhanced solubility/activity, making the process of strain development faster and more efficient than in traditional microbial expression host strain development. Dozens of host strains are tested in parallel to identify expression strategy/host cell combinations that result in improved target protein accumulation and/or stability. The technology is easily employed in traditional fermentation, recovery and purification settings with no need for additional, unique equipment.

About Dowpharma^sm

Dowpharma^sm contract manufacturing services provides the pharmaceutical and biopharmaceutical industries with innovative technologies, products and services for clients in drug discovery, development, manufacturing and delivery. Dowpharma offers process development, route selection, methods development, chiral capabilities and associated analytical services as well as manufacturing and scale-up from feasibility, through clinical trials, to commercial launch. Dowpharma currently manufactures small molecule APIs and intermediates, catalysts, cGMP polymers, and poly(ethylene) glycols (PEGs) and provides technology for protein expression through microbial fermentation.

For more information on Dowpharma visit www.dowpharma.com.

About Dow

For Editorial Information:

Michael Altmann
The Dow Chemical Company
(732) 563-5088

	Pfēnex
Capabilities Molecular Biology Fermentation Process Development Purification Process Development Analytical Development Pilot Manufacturing Process Technology and Documentation Project Lifecycle Timeline Literature and Resources News /pfenex/news/20070515a.htm /pfenex/news/20070501a.htm /pfenex/news/20070430a.htm /pfenex/news/20070227a.htm /pfenex/news/20070222a.htm /pfenex/news/20060410a.htm /pfenex/news/20060407a.htm /pfenex/news/20060228a.htm /pfenex/news/20060214a.htm Events Calendar Contact Us	Dowpharma^SM and Cygnus Technologies, Inc. Announce Launch of Pseudomonas fluorescens Host Cell Protein Kit Kit intended for release testing of biopharmaceuticals expressed in Pseudomonas fluorescens Midland, MI and Southport, NC - April 30, 2007 Dowpharma^SM, a business unit of The Dow Chemical Company, and Cygnus Technologies, Inc. today announced that Cygnus has launched a new kit for testing for the presence of host cell proteins in proteins expressed in Pseudomonas fluorescens. “This new kit will enable users of Dowpharma Pfēnex Expression Technology™ to routinely test their products for the presence of host cell protein with a fully validated method,” said Charles Squires, R&D director, Dowpharma. “Cygnus Technology is the leading provider of cell protein detection kits and we are very happy that they decided to develop and launch a kit for Pseudomonas fluorescens.” Ken Hoffman, president at Cygnus Technologies said, “More and more pharmaceutical and biotech companies have been adopting the Pfēnex Expression Technology, and we have responded to this growing need by providing a fully validated test that will satisfy the industry’s need for accurate, rapid and cost-effective QC measures.” About Cygnus Technologies, Inc. Cygnus Technologies, Inc. provides the Biotechnology and Biopharmaceutical industry with products and analytical methods, designed to accelerate the R&D phase, improve process development and reduce the costs associated with labor intensive quality control procedures. We offer a comprehensive menu of well validated convenient to use microtiter plate ELISA methods to detect Host Cell Proteins from specific recombinant expression systems and bioprocess contaminants used in culture media as well as transgenic expression systems in goats and cattle. These simple-to-use kits are highly sensitive and are intended to aid in optimal purifications process development and routine quality control. More information about Cygnus can be found at www.cygnustechnologies.com About Pfēnex Expression Technology™ Using a natural isolate of Pseudomonas fluorescens, an abundant and non-infectious component of the microbial flora of soil, water, and plants, many high performance production strains have been developed. Proteins are expressed in high yields with correct disulfide bond formation, reduced proteolytic degradation and enhanced solubility/activity, making the process of strain development faster and more efficient than in traditional microbial expression host strain development. Dozens of host strains are tested in parallel to identify expression strategy/host cell combinations that result in improved target protein accumulation and/or stability. The technology is easily employed in traditional fermentation, recovery and purification settings with no need for additional, unique equipment. About Dowpharma^sm Dowpharma^sm contract manufacturing services provides the pharmaceutical and biopharmaceutical industries with innovative technologies, products and services for clients in drug discovery, development, manufacturing and delivery. Dowpharma offers process development, route selection, methods development, chiral capabilities and associated analytical services as well as manufacturing and scale-up from feasibility, through clinical trials, to commercial launch. Dowpharma currently manufactures small molecule APIs and intermediates, catalysts, cGMP polymers, and poly(ethylene) glycols (PEGs) and provides technology for protein expression through microbial fermentation. For more information on Dowpharma visit www.dowpharma.com. About Dow For Editorial Information: Michael Altmann The Dow Chemical Company (732) 563-5088
	Pfēnex Home Dow Home Privacy Statement Terms of Use Accessibility Statement Site Map Copyright © The Dow Chemical Company (1995-2009). All Rights Reserved.